Affimed is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapy treatments for cancer
The company's proprietary platform harnesses the power of the immune system by designing next-generation bispecific antibodies that can specifically target and engage immune cells to attack and eliminate tumor cells. Affimed aims to create highly effective, targeted therapies that not only improve patient outcomes but also enhance the overall treatment experience, working on various candidates in its pipeline to advance the future of cancer care.
Affimed shares surged after positive updates from the AFM24-102 study in NSCLC. The study reported a 71% disease control rate and significant clinical activity, highlighting potential efficacy of AFM24 with atezolizumab.
Affimed shares are trading higher Monday after the company announced additional follow-up data from the on-going AFM24-102 study in non-small cell lung cancer (NSCLC).
Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million.
Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares surged 358% to $134.37 in pre-market trading after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge Capital Acquisition Corp.
